Open AccessEffects of Vitamin D Supplementation in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Author(s) -
Yali Wei,
Shuli Wang,
Meng Yue,
Qing-Tao Yu,
Qian Wang,
Xu Hu,
Huacai Yuan,
Xiaoxu Li,
Liyong Chen
Publication year - 2020
Publication title -
international journal of endocrinology and metabolism/international journal of endocrinology and metabolism.
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.652
H-Index - 23
eISSN - 1726-9148
pISSN - 1726-913X
DOI - 10.5812/ijem.97205
Subject(s) - medicine , nonalcoholic fatty liver disease , meta analysis , gastroenterology , insulin resistance , confidence interval , randomized controlled trial , cochrane library , fatty liver , placebo , endocrinology , insulin , disease , pathology , alternative medicine
Context: Vitamin D (VD) has been found to play a key role in nonalcoholic fatty liver disease (NAFLD). This meta-analysis explored the effects of VD supplementation in patients with NAFLD. Methods: The PubMed, EMBASE, and the Cochrane Library databases were searched to find randomized control trials (RCTs) that measured the changes between the VD supplement group and the control group until May 2019. Standard mean difference (SMD) with 95% confidence intervals (CI) was calculated when data units were different, otherwise weighted mean difference (WMD) and 95% CI was calculated. Heterogeneity was assessed using the I2 statistic. Results: Eight RCTs with 624 individuals were extracted. The main indicators, including serum alanine aminotransferase (WMD = -0.052; 95% CI: -3.740, 3.636; P = 0.978) and aspartate aminotransferase concentrations (WMD = -0.479; 95% CI: -2.791, 1.833; P = 0.685) were not significantly different between the intervention and placebo groups. In addition, no significant intergroup difference was observed in the following secondary indicators: fasting blood glucose (WMD = 0.466; 95% CI: -5.313, -10.879; P = 0.061), homeostasis model assessment (WMD = 0.380, 95% CI: -0.162, 0.923; P = 0.169), serum insulin concentration (WMD = 0.760; 95% CI: -0.532, 2.052; P = 0.249), high-density lipoprotein (WMD = -0.012; 95% CI: -0.188, 0.164; P = 0.891), and low-density lipoprotein (WMD = -0.115; 95% CI: -3.849, -3.620; P = 0.952). Conclusions: The results indicate that VD supplementation does not improve liver enzymes, insulin resistance, glucose metabolism parameters, and lipid levels in patients with NAFLD.